Brisbane Clinical Trials
The Access Study
The study drug is a biosimilar of an already approved drug used to treat life-threatening diseases of the blood.
8 nights
5 phone calls + 8 visits
- Study Objective: To evaluate the efficacy and safety of a biosimilar for treating PNH and aHUS.
- Understanding PNH and aHUS: PNH and aHUS are life-threatening blood diseases that can lead to severe complications.
- Importance of Biosimilars: Biosimilars provide more affordable treatment options and can prevent medicine shortages.
- Clinical Trial Details:
- The trial is designed to offer an alternative to high-cost medications, ensuring wider patient access and affordability
- An independent ethics committee has approved this clinical trial.
- Participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!
Eligibility
Biological Sex Male
Age 18 – 55 years old
Weight 50kg - 95kg
BMI 18 - 30 kg/m²
Medical History No significant medical history
Medication Not taking any medication
Smoking History Non-smoker or light smokers (<5 cigarettes/day)